**Autoimmune Processes in Multiple Sclerosis: Production of Harmful Catalytic Antibodies Associated with Significant Changes in the Hematopoietic Stem Cell Differentiation and Proliferation**

Georgy A. Nevinsky

[249] Brettschneider J, Jaskowski TD, Tumani H*, et al.* Serum anti‐GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmu‐

[250] Thiele GM, Duryee MJ, Anderson DR*, et al.* Malondialdehyde‐acetaldehyde adducts and anti‐malondialdehyde‐acetaldehyde antibodies in rheumatoid arthritis. Arthr

[251] Boullerne AI, Rodriguez JJ, Touil T*, et al.* Anti‐S‐nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis:

[252] Qin J, Goswami R, Balabanov R*, et al.* Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res 2007; 85(5): 977–84.

[253] Ho PP, Kanter JL, Johnson AM*, et al.* Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci Transl Med 2012; 4(137): 137ra73.

[254] Pasquali L, Pecori C, Chico L*, et al.* Relation between plasmatic and cerebrospinal fluid oxidative stress biomarkers and intrathecal Ig synthesis in multiple sclerosis patients.

[255] Eggleton P, Nissim A, Ryan BJ*, et al.* Detection and isolation of human serum autoan‐ tibodies that recognize oxidatively modified autoantigens. Free Radic Biol Med 2013;

[256] Merbl Y, Kirschner MW. Protein microarrays for genome‐wide posttranslational modification analysis. Wiley Interdiscip Rev Syst Biol Med 2011; 3(3): 347–56.

implications for multiple sclerosis. J Neurosci 2002; 22(1): 123–32.

nol 2009; 217(1–2): 95–101.

98 Trending Topics in Multiple Sclerosis

Rheumatol 2015; 67(3): 645–55.

J Neuroimmunol 2015; 283:39–42).

57:79–91.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/63824

#### **Abstract**

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. MS pathogenesis is not clear. Destruction of myelin by inflammation caused by autoimmune reactions has been proposed. Interestingly, healthy humans usually do not develop abzymes (Abzs). It was shown that DNase and MBP-hydrolyzing Abzs are easily detectable at the beginning of autoimmune diseases (ADs) including MS, when concentrations of antibodies to autoantigens are not yet significantly increased and correspond to levels in healthy donors. In addition, the relative enzymatic activity of antibodies from cerebrospinal fluid (CSF) is ~50-fold higher than that from the sera of the same MS patients. Experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice, a model mimicking relevant aspects of human MS was used. During develop‐ ment of spontaneous and MOG35-55-induced EAE in C57BL/6 mice, a specific reorganization of the immune system of mice was observed. It leads to a condition which was associated with the generation of catalytically active IgGs-hydrolyzing DNA, myelin basic protein (MBP), and MOG. Production of Abzs was associated with increased proteinuria, leading changes in differentiation of mice bone marrow hematopoietic stem cells (HSCs) and an increase in proliferation of lymphocytes in bone marrow, spleen, and thymus as well as a significant suppression of cell apoptosis in these organs. Treatment of control non-autoimmune CBA mice with MOG led to the different differentiation and proliferation of HSCs comparing with EAE C57BL/6 mice. The treatment of EAE mice with cuprizone inducing demyelination lead to a signifi‐ cant decrease in the size of the brain corpus callosum, but do not significantly change the differentiation profile of HSCs differentiation when compared with untreated mice. It indicates that cuprizone treatment is associated with demyelination, but not autoimmune reactivity. The possible differences in immune system reorganizations

© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

during preclinical phases of the disease, acute and late EAE, leading to production of different autoantibodies and Abzs as well other changes are discussed.

**Keywords:** catalytic antibodies, autoimmunity, hematopoietic stem cells, multiple sclerosis, cell differentiation, cell proliferation
